During the past decades topology optimization techniques have been shown to be efficient tools to conceive these kinds of distributed compliant mechanisms.
Over the last decades, heuristic optimization methods based on imitating natural, biological, social or cultural processes on a computational level have aroused the interest of the scientific community due to their ability to effectively explore multimodal and multidimensional solution spaces.
Over the past few decades, topology optimization has emerged as a powerful and useful tool for the design of structures, also exploiting the ever growing computational speed and power.
During the recent decade, truss optimization by meta-heuristics has gradually replaced deterministic and optimality criteria-based methods.
This strategy enables the use of decades of optimizations incorporated in nowadays DBMSs and portable to encrypted data.
In recent decades, several optimization-based methods have been developed for the proportional-integral-derivative (PID) controller design, and the common feature of these methods is that the controller has only one adjustable parameter.
Most research in the last decades considered these optimization techniques separately, seeking an initial optimal material layout and refining the shape of the solution later.
Many decades of heuristic optimization have gone into perfecting conventional cell culture devices and protocols.
This paper presents a critical review of research and development on surface texturing over the past decades, highlighting design, optimization and fabrication of surface texture, and their effects on tribological performance in terms of friction and load bearing capacity under different lubrication regimes.
The relatively high cell numbers achieved over more than two decades of process optimization strategies utilising media and fed batch cultivation improvements [ 1, 2] resulted in product titres of more than 5 g/l.
Following a decade of preclinical optimization, CAR-T cell therapy has produced impressive clinical results in treating patients with relapsed or refractory B cell leukemia and lymphoma whose treatment options are limited and prognosis is poor.
